

RELapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities

RELENT

FACTS & FIGURES

RELapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities is a multidisciplinary group of nine scientific partners and four SMEs from Europe and Australia funded by the European Union's Horizon 2020 research and innovation programme. The project started in November 2015 and will run for 4.5 years.

RELENT was launched to address the unmet need for better ways to individualise the treatment of chronic autoimmune and inflammatory diseases thereby reducing the unacceptably high morbidity and mortality they cause.



© jarun011, RELENT, Syda Productions - Fotolia.com

OBJECTIVES

The overarching objectives of RELENT are:

- Understand common mechanisms of diseases and their relation in co-morbidities thereby transforming the clinical outcome for patients with severe autoimmune and inflammatory diseases
- Provide the scientific underpinning by closing the knowledge in common mechanisms of disease. This should result in a more individualised and thus safer, and more effective, management for severe immune-mediated disease in affected females and males.

SPECIFIC AIMS

The programme has four specific aims:

- Combine subset analysis of genome wide association studies with classical cell biology to uncover pathways that influence the outcome of chronic autoimmune and inflammatory disease and the response to treatment in women and men.
- Identify protein signatures that predict the outcome of severe immune-mediated disease, using multiplexed antigen array and whole proteome analysis and mass spectrometry analysis.
- Characterise T and B cell abnormalities that predispose to autoimmunity and infection by studying the ageing immune system in health and disease.
- Analyse pathogenic effector T cells and their control by macrophages and dendritic cells and the molecules they secrete using normal and transgenic mice expressing human proteins.

CONSORTIUM

The RELENT Consortium is a multidisciplinary group of scientists and clinical investigators. The whole group consists of 12 partners from 6 different European countries, and 1 partner from Australia whose expertise is not available elsewhere in the world.



IMPACT

RELENT will have a considerable impact in many areas. It will be particularly:

- Closely collaborate with patient's organisations giving them relevant target groups rapid information about the latest research results & access to participation in clinical studies
- Minimize treatment-associated toxicities, disease-related damage and long-term morbidity and reduce health care costs
- Allow predictive monitoring and individualised treatment minimizing drug toxicities and secondary co-morbidities.
- Validate and implement methods to measure disease activity and monitor treatment more accurately thus avoiding drug toxicity and side effects such as infections.

CONTACT

RELENT Project Coordinator
Prof. Renate Kain, M.D., Ph.D.
Medical University of Vienna

renate.kain@meduniwien.ac.at
info@relent.eu

<https://www.relent.eu>

Relent_EU

Relent-project



RELENT has received funding from the European Union's Horizon 2020 research programme under grant agreement No 668036. The views expressed here are those of the authors only. The EU Commission takes no responsibility for any use made of the information set out.

Monash University has received funding for RELENT from the National Health and Research Council Australia via the European Union Collaborative Research Grant

